No Data
BEIGENE (06160) issued 1.0076 million shares due to the exercise of stock options.
BEIGENE (06160) announced that it will issue common stock due to a Director exercising stock options on March 6, 2025...
China's Policy Reforms Gain Momentum
Express News | Form 144 | BeiGene(ONC.US) Officer Proposes to Sell 10.39 Million in Common Stocks
BEIGENE (06160.HK) granted a total of 0.0326 million restricted stock units.
On March 6, 2023, GELONGHUI announced that BEIGENE (06160.HK) granted Options to one grantee for a total of 1,100 American Depositary Shares on March 3, 2025, and granted Restricted Stock Units involving a total of 32,579 American Depositary Shares to one hundred and fifty-one grantees according to the terms of the 2016 Options and Incentive Plan.
HAITONG INT'L: Initiated coverage on BEIGENE (06160) with an "Outperform" rating and a Target Price of HKD 182.35.
The bank believes that the company's BTK inhibitors + BCL-2 inhibitors + BTK CDAC are expected to continue to deepen its leadership position in hematologic malignancies.
[Brokerage Focus] HAITONG INT'L gives BEIGENE (06160) an initial “Outperform” rating, pointing out that the company is expected to turn a profit by 2025.
Jinwu Financial News | HAITONG INT'L published a Research Report stating that BEIGENE (06160) has more than 60 clinical stage projects currently undergoing clinical trials globally, as well as 17 commercial products. Among them, the core products, zanubrutinib (BTK inhibitor) and tislelizumab (PD-1 inhibitor), have been commercialized in multiple regions including China, the United States, and Europe. The Global capabilities in R&D, clinical, production, and commercialization are BEIGENE's core competitiveness. In the future, the company is expected to grow into an MNC rooted in China. The firm noted that 2025 will be a key turning point for BEIGENE's fundamentals, as the overseas sales of zanubrutinib continue to increase, and BEIGENE is likely to turn a profit at the net level.
